Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bio-Thera Solutions Has China’s First Adalimumab Biosimilar

Qletli Is Only The Second Biosimilar Approved In China

Executive Summary

Bio-Thera Solutions has secured only the second biosimilar approval ever from China’s NMPA, and the country’s first biosimilar approval for a rival to Humira (adalimumab).

You may also be interested in...



Shanghai Junshi Announces Chinese Adalimumab Approval

Shanghai Junshi and Mabwell have received approval from China’s NMPA for their co-developed adalimumab biosimilar rival to Humira.

Bio-Thera Conducts Simponi Phase III Trial

China’s Bio-Thera Solutions has announced the start of Phase III trials for its BAT2506 proposed biosimilar golimumab rival to Janssen’s Simponi.

Pfizer Fails To Make Its Mark In China-Focused Biosimilars Market

Pfizer threw in the towel for biosimilar development in China last week, just three years after opening its $350m Global Biotechnology Center, based in the Hangzhou Economic Development Area.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB149350

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel